CVRx, Inc. (NASDAQ: CVRX) Securities Class Action

USDC – District of Minnesota

november 9, 2026

CLASS PERIOD: july 25, 2023 – august 6, 2026
LEAD PLAINTIFF DEADLINE: january 8, 2027

Please complete the form below to contact Kaplan Fox regarding the CVRx class action:

Principal Contacts

About the CVRx class action lawsuit

A securities class action has been filed against CVRx, Inc. (NASDAQ: CVRX) on behalf of investors who purchased or otherwise acquired CVRx securities between July 25, 2023 and August 6, 2026 (the “Class Period”). The case was filed on November 9, 2026 in the U.S. District Court for the District of Minnesota.

Investors who want to ask the court to appoint them lead plaintiff must do so by January 8, 2027. If you invested in CVRx during the Class Period and lost money, contact Kaplan Fox using the form on this page, by emailing pmayer@kaplanfox.com, or by calling (646) 315-9003.

What the lawsuit alleges

According to the complaint, CVRx manufactures, markets and sells an implantable medical device called Barostim that uses neuromodulation to “improve the symptoms” of patients with heart failure. This case concerns the defendants’ allegedly false and misleading statements and/or failure to disclose that in order to induce sales growth, CVRx and its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act.

What happened to CVRx stock

On August 6, 2026, after the market close, according to the complaint, CVRx disclosed in its Form 10-Q for the second quarter that on May 14, 2026, the Company “received a civil investigative demand (‘CID’) from the U.S. Department of Justice in connection with an investigation under the False Claims Act.” The CID allegedly concerns “whether [CVRx] caused the submission of false claims to government health insurance programs by improperly marketing [its] device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs.” The complaint also alleges that CVRx cut its outlook on August 6, 2026 based, in part, on weak sales force productivity.

On this news, CVRx common stock fell $3.55 per share (or 60%), from $5.94 per share on August 6, 2026, to close at $2.39 per share on August 7, 2026.

Who may be eligible

The proposed class includes investors who purchased or otherwise acquired CVRx securities between July 25, 2023 and August 6, 2026. If you bought during that period and lost money, you may be a member of the class.

Lead plaintiff deadline: January 8, 2027

A lead plaintiff is an investor the court appoints to represent the class and oversee the case on its behalf. Class members who want to serve in that role must move the court no later than January 8, 2027. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you have losses, contact us to learn more about the lead plaintiff process.

Case updates

• November 9, 2026: Complaint filed in the District of Minnesota.
• January 8, 2027: Deadline to ask the court to be appointed lead plaintiff.

Frequently asked questions

Do I have to become lead plaintiff to recover?

No. You need not seek to become a lead plaintiff in order to share in any possible recovery.

What if I bought CVRx outside the Class Period?

The complaint as filed covers purchases between July 25, 2023 and August 6, 2026. Contact us if you are not sure whether your purchases qualify.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com